1. BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. (June 2017) Authors: Kim, Y.H.; Prince, H.M.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.L.; Wolter, P.; Bechter, O.; Wang, Y.; Palanca‐Wessels, M.C.; Wood, K.W.; Li, M.; Liu, Y.; Lin, H.; Little, M.; Danaee, H.; Trepicchio, W.; Dummer, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis. (27th March 2020) Authors: Schöffski, P.; Timmermans, I.; Hompes, D.; Stas, M.; Sinnaeve, F.; De Leyn, P.; Coosemans, W.; Van Raemdonck, D.; Hauben, E.; Sciot, R.; Clement, P.; Bechter, O.; Beuselinck, B.; Woei-A-Jin, F. J. S. H.; Dumez, H.; Nafteux, P.; Wessels, T. Other Names: Lewis Valerae O. Academic Editor. Journal: Sarcoma Issue: Volume 2020(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Corrigendum to "Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis". (8th February 2021) Authors: Schöffski, P.; Timmermans, I.; Hompes, D.; Stas, M.; Boecxstaens, Veerle; Sinnaeve, F.; De Leyn, P.; Coosemans, W.; Van Raemdonck, D.; Hauben, E.; Sciot, R.; Clement, P.; Bechter, O.; Beuselinck, B.; Woei-A-Jin, F. J. S. H.; Dumez, H.; Nafteux, P.; Wessels, T. Journal: Sarcoma Issue: Volume 2021(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dabrafenib plus trametinib in BRAF K601E‐mutant melanoma. (1st February 2019) Authors: Rogiers, A.; Thomas, D.; Vander Borght, S.; van den Oord, J.J.; Bechter, O.; Dewaele, M.; Rambow, F.; Marine, J.‐C.; Wolter, P. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: 421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Dabrafenib plus trametinib in BRAF K601E‐mutant melanoma. (22nd November 2018) Authors: Rogiers, A.; Thomas, D.; Vander Borght, S.; van den Oord, J.J.; Bechter, O.; Dewaele, M.; Rambow, F.; Marine, J.‐C.; Wolter, P. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: 421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL). (12th June 2019) Authors: Horwitz, S.M.; Scarisbrick, J.; Prince, H.M.; Whittaker, S.; Duvic, M.; Kim, Y.H.; Quaglino, P.; Zinzani, P.L.; Bechter, O.; Eradat, H.; Pinter‐Brown, L.; Akilov, O.; Geskin, L.; Sanches, J.; Ortiz‐Romero, P.; Lisano, J.; Brown, L.; Palanca‐Wessels, M.C.; Gautam, A.; Bunn, V. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 286 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗